Syndax Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Syndax Pharmaceuticals, Inc. (SNDX) reported Basic Shares Outstanding (Weighted Average) of 88.99 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 88.99M shares, a 3.07% increase year-over-year.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 88.26M shares, a 2.42% increase year-over-year.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 86.91M shares, a 0.40% increase year-over-year.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 86.62M shares, a 1.39% increase year-over-year.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 86.63M shares, a 1.17% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 85.62M shares, a 21.67% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 70.37M shares, a 15.82% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 60.76M shares, a 16.70% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 88.99M shares 10-Q · filed 2026-08-04 | 88.63M shares 10-Q · filed 2026-08-04 | 88.05M shares derived: average of 3 quarters · filed 2026-08-04 | 87.69M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 88.26M shares 10-Q · filed 2026-04-30 | 87.58M shares derived: average of 2 quarters · filed 2026-04-30 | 87.26M shares derived: average of 3 quarters · filed 2026-04-30 | 87.03M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | 86.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 86.76M shares derived: average of 2 quarters · filed 2026-02-26 | 86.62M shares derived: average of 3 quarters · filed 2026-08-04 | 86.63M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 86.62M shares 10-Q · filed 2025-11-03 | 86.48M shares derived: average of 2 quarters · filed 2026-08-04 | 86.53M shares 10-Q · filed 2025-11-03 | 86.42M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | 86.34M shares 10-Q · filed 2026-08-04 | 86.26M shares 10-Q · filed 2026-08-04 | 86.36M shares derived: average of 3 quarters · filed 2026-08-04 | 86.13M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | 86.17M shares 10-Q · filed 2026-04-30 | 86.37M shares derived: average of 2 quarters · filed 2026-04-30 | 86.06M shares derived: average of 3 quarters · filed 2026-04-30 | 85.86M shares derived: average of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | 86.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 86.00M shares derived: average of 2 quarters · filed 2026-02-26 | 85.76M shares derived: average of 3 quarters · filed 2026-02-26 | 85.62M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 85.43M shares 10-Q · filed 2025-11-03 | 85.35M shares derived: average of 2 quarters · filed 2025-11-03 | 85.31M shares 10-Q · filed 2025-11-03 | 82.12M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 85.27M shares 10-Q · filed 2025-08-04 | 85.24M shares 10-Q · filed 2025-08-04 | 81.01M shares derived: average of 3 quarters · filed 2026-02-26 | 78.22M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 85.21M shares 10-Q · filed 2025-05-05 | 78.88M shares derived: average of 2 quarters · filed 2026-02-26 | 75.87M shares derived: average of 3 quarters · filed 2026-02-26 | 74.31M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 72.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 71.20M shares derived: average of 2 quarters · filed 2026-02-26 | 70.68M shares derived: average of 3 quarters · filed 2026-02-26 | 70.37M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 69.86M shares 10-Q · filed 2024-11-05 | 69.75M shares derived: average of 2 quarters · filed 2024-11-05 | 69.65M shares 10-Q · filed 2024-11-05 | 68.04M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | 69.64M shares 10-Q · filed 2024-08-01 | 69.54M shares 10-Q · filed 2024-08-01 | 67.43M shares derived: average of 3 quarters · filed 2025-03-03 | 65.74M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | 69.44M shares 10-Q · filed 2024-05-08 | 66.33M shares derived: average of 2 quarters · filed 2025-03-03 | 64.44M shares derived: average of 3 quarters · filed 2025-03-03 | 63.37M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | 63.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 61.94M shares derived: average of 2 quarters · filed 2025-03-03 | 61.35M shares derived: average of 3 quarters · filed 2025-03-03 | 60.76M shares 10-K · filed 2025-03-03 |
| 2022-09-30 | 60.67M shares 10-Q · filed 2023-11-02 | 60.41M shares derived: average of 2 quarters · filed 2023-11-02 | 59.94M shares 10-Q · filed 2023-11-02 | 58.25M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 60.16M shares 10-Q · filed 2023-08-03 | 59.57M shares 10-Q · filed 2023-08-03 | 57.44M shares derived: average of 3 quarters · filed 2024-02-27 | 56.07M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 58.98M shares 10-Q · filed 2023-05-08 | 56.08M shares derived: average of 2 quarters · filed 2024-02-27 | 54.71M shares derived: average of 3 quarters · filed 2024-02-27 | 53.93M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 53.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 52.58M shares derived: average of 2 quarters · filed 2024-02-27 | 52.25M shares derived: average of 3 quarters · filed 2024-02-27 | 52.06M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 51.96M shares 10-Q · filed 2022-11-03 | 51.78M shares derived: average of 2 quarters · filed 2022-11-03 | 51.69M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 51.60M shares 10-Q · filed 2022-08-08 | 51.55M shares 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | 41.31M shares 10-K · filed 2023-02-28 | |||
| 2019-12-31 | 30.49M shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |